Optivise Advisory Services’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$681K Buy
2,706
+309
+13% +$66.5K 0.35% 85
2026
Q1
$521K Sell
2,397
-235
-9% -$52.1K 0.32% 84
2025
Q4
$601K Buy
2,632
+705
+37% +$161K 0.35% 80
2025
Q3
$446K Buy
1,927
+411
+27% +$83.7K 0.27% 93
2025
Q2
$281K Buy
1,516
+90
+6% +$16.7K 0.14% 144
2025
Q1
$299K Sell
1,426
-398
-22% -$77.4K 0.17% 128
2024
Q4
$324K Buy
1,824
+450
+33% +$82.7K 0.17% 117
2024
Q3
$271K Sell
1,374
-833
-38% -$155K 0.14% 132
2024
Q2
$378K Buy
+2,207
New +$366K 0.2% 107

Other funds holding ABBV

Optivise Advisory Services's ABBV Position: Q2 2026 in Review

Optivise Advisory Services increased its AbbVie (ABBV) stake by 13% in Q2 2026, buying an estimated $66.5K and bringing the position to 2,706 shares worth $681K. The position accounts for 0.35% of the portfolio, ranked #85.

Optivise Advisory Services first reported a position in ABBV in Q2 2024 and has held it in 9 quarters since. 1,547 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Optivise Advisory Services held 2,706 shares of AbbVie worth $681K as of Q2 2026.
  • Optivise Advisory Services bought 309 AbbVie shares in Q2 2026, an estimated $66.5K.
  • AbbVie made up 0.35% of Optivise Advisory Services's portfolio in Q2 2026, its #85 holding.
  • Optivise Advisory Services first reported a position in AbbVie in Q2 2024 and has held it in 9 quarters since.
  • 1,547 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Optivise Advisory Services's 13F filing for Q2 2026, filed 13 Jul 2026.